PharmaCyte Biotech PMCB Estimates

NASDAQ PMCB
$0.40 -0.01 (-1.63%)
As of: Oct 1, 2026 · 3:59 PM EDT
Analyst Estimates

PharmaCyte Biotech, Inc. Revenue Estimates

Periods 3

The most recent reported quarter, Q4 21, came in at 0.00.

Metric Q2 21Q3 21Q4 21
Reported (Actual) 0.000.000.00
High Estimate 0.000.000.00
Low Estimate 0.000.000.00
Consensus Estimate 0.000.000.00
Analyst Estimates

PharmaCyte Biotech, Inc. Earnings Per Share (EPS) Estimates

Periods 15
Next Period Q1 22
Consensus -0.07

Analysts expect PharmaCyte Biotech, Inc. to report earnings per share of -0.07 for Q1 22, against a range of -0.07 to -0.07. The most recent reported quarter, Q4 24, came in at 1.20, a 955.5% beat against the -0.14 consensus.

Metric Q2 21Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24
Reported (Actual) -0.06-0.04-0.07--------1.20
High Estimate -0.06-0.05-0.04-0.07-0.08-0.07-0.08-0.07-0.09-0.09-0.10-0.13
Low Estimate -0.06-0.05-0.04-0.07-0.08-0.09-0.08-0.09-0.09-0.09-0.12-0.15
Consensus Estimate -0.06-0.05-0.04-0.07-0.08-0.08-0.08-0.08-0.09-0.09-0.11-0.14

PharmaCyte Biotech, Inc. Estimates API

Pull Wall Street consensus for PharmaCyte Biotech, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=PMCB&mode=revenue&api_key=YOUR_API_KEY